title: Novel Bone-Targeting Agent for Enhanced Delivery of Vancomycin to Bone.
abstract: We examined the pharmacokinetic properties of vancomycin conjugated to a bone-targeting agent (BT) with high affinity for hydroxyapatite after systemic intravenous administration. The results confirm enhanced persistence of BT-vancomycin in plasma and enhanced accumulation in bone relative to vancomycin. This suggests that BT-vancomycin may be a potential carrier for the systemic targeted delivery of vancomycin in the treatment of bone infections, potentially reducing the reliance on surgical debridement to achieve the desired therapeutic outcome.
authors.affiliation: College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
authors.forename: Zaineb A F
authors.initials: ZA
authors.lastname: Albayati
authors.affiliation: Saha Cardiovascular Research Center, University of Kentucky, Lexington, Kentucky, USA.
authors.forename: Manjula
authors.initials: M
authors.lastname: Sunkara
authors.affiliation: Department of Laboratory Medicine and Pathology Mayo Clinic, Rochester, Minnesota, USA.
authors.forename: Suzannah M
authors.initials: SM
authors.lastname: Schmidt-Malan
authors.affiliation: Department of Laboratory Medicine and Pathology Mayo Clinic, Rochester, Minnesota, USA.
authors.forename: Melissa J
authors.initials: MJ
authors.lastname: Karau
authors.affiliation: Saha Cardiovascular Research Center, University of Kentucky, Lexington, Kentucky, USA.
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Morris
authors.affiliation: Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
authors.forename: James M
authors.initials: JM
authors.lastname: Steckelberg
authors.affiliation: Department of Laboratory Medicine and Pathology Mayo Clinic, Rochester, Minnesota, USA Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
authors.forename: Robin
authors.initials: R
authors.lastname: Patel
authors.affiliation: College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Breen
authors.affiliation: Department of Microbiology and Immunology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
authors.forename: Mark S
authors.initials: MS
authors.lastname: Smeltzer
authors.affiliation: Department of Chemistry, University of Louisville, Louisville, Kentucky, USA.
authors.forename: K Grant
authors.initials: KG
authors.lastname: Taylor
authors.affiliation: Pradama, Inc., Louisville, Kentucky, USA.
authors.forename: Kevyn E
authors.initials: KE
authors.lastname: Merten
authors.affiliation: Department of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky, USA wmpier01@louisville.edu pacrooks@uams.edu.
authors.forename: William M
authors.initials: WM
authors.lastname: Pierce
authors.affiliation: College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA wmpier01@louisville.edu pacrooks@uams.edu.
authors.forename: Peter A
authors.initials: PA
authors.lastname: Crooks
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001842:Bone and Bones / Q000378:metabolism; D003646:Debridement; D004195:Disease Models, Animal; D004337:Drug Carriers / Q000627:therapeutic use*; D017886:Durapatite / Q000378:metabolism*; D006801:Humans; D010019:Osteomyelitis / Q000188:drug therapy* / Q000382:microbiology; D011092:Polyethylene Glycols / Q000737:chemistry; D051381:Rats; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects; D014640:Vancomycin / Q000008:administration & dosage* / Q000493:pharmacokinetics* / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D004337:Drug Carriers; D011092:Polyethylene Glycols; D014640:Vancomycin; D017886:Durapatite